Protagen AG. (1/12/10). "Press Release: Protagen AG Appoints New Board Members". Dortmund.

	Region	Dortmund
	Country	Germany
	Organisation	Protagen AG
	Group	Protagen (Group)
	Organisation 2	Qiagen (Group)
	Product	in vitro diagnostics (IVD)
	Product 2	proteomics
	Person	Schulz-Knappe, Peter (Protagen 201001– head Protein Services before Proteome Sciences plc CEO before BioVisioN CEO)
	Person 2	Schweins, Thomas (Qiagen 200402– VP Corporate Strategy before Boston Consulting Dusseldorf before Hoechst)

The specialist for in-vitro diagnostics and GMP-compliant protein analysis appoints two new members for the Executive Board.

Dr. Peter Schulz-Knappe, former CSO at Proteome Sciences plc., started his new position with the beginning of the year. He will take over operational responsibility for the Business Unit Diagnostics. At the same time, Martin Blüggel, cofounder and COO, joins the board and will manage the Business Unit Protein Services. „The new Executive Board of Protagen AG underscores the new strategic positioning in the attractive area of in-vitro diagnostics, and strengthens the business with our customers in pharma and biotech”, says Dr. Stefan Müllner, CEO, and adds “Peter Schulz-Knappe is an international renowned expert in biomarker discovery and their targeted development into new in-vitro diagnostics. Therefore, he is the ideal completion of our management team.”

Furthermore, Dr. Thomas Schweins, Member of the Executive Committee of Qiagen and Vice President Marketing & Strategy, completes the Supervisory Board. Dr. Schweins, a trained biochemist, is a professional expert in the global diagnostic businesses. Before joining Qiagen, he held positions in the Pharma/Health Care Unit of Boston Consulting Group, and as project manager at Hoechst AG/Aventis SA.

Background: Within the last four years, Protagen developed a strong international market position in the area of GMP-compliant protein analytical services, and belongs to the preferred partners of pharma and biotech companies. Furthermore, Protagen has developed UNIarray®, a unique technology platform for the development of novel in-vitro diagnostics, which allows the indication specific determination of autoantibody signatures in patient sera. Proprietary biomarker panels for differential diagnosis of Prostate Cancer and Multiple Sclerosis are currently validated in a multicentric clinical study.

About Protagen AG

Protagen AG (www.protagen.de) is an international leading specialist in the fields of diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.

Contact

Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de

Media Enquiries
Bettina Franz
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: bettina.franz@protagen.de

Record changed: 2011-12-29

Follow Us!

Top News

Upcoming Events

Associations

Partners

Protagen AG. (1/12/10). "Press Release: Protagen AG Appoints New Board Members". Dortmund.

More documents for Protagen (Group)